Navigation Links
Gynecologic cancer expert helps pinpoint best treatment for fast-growing gestational tumors
Date:4/25/2011

DALLAS April 26, 2011 A clinical trial has sifted out the most effective single-drug chemotherapy regimen for quick-growing but highly curable cancers that arise from the placentas of pregnant women.

In the comparison trial for treating low-risk gestational trophoblastic neoplasia (GTN), researchers found that a biweekly dose of dactinomycin had a higher complete response rate than a weekly dose of methotrexate, the more commonly used drug. GTN is a group of rare tumors that involve abnormal growth of cells inside a woman's uterus.

"Both chemotherapy drugs are effective in treating this kind of neoplasia, but this trial proved that dactinomycin is the best first-line regimen," said Dr. David Scott Miller, who is the head of gynecologic oncology at UT Southwestern Medical Center and co-investigator on the study.

The trial, supported by grants from the National Cancer Institute to the Gynecologic Oncology Group, was published in the March issue of the Journal of Clinical Oncology.

Dr. Miller, professor of obstetrics and gynecology, chairs the uterine corpus committee of the Gynecologic Oncology Group. As group members, UT Southwestern specialists are able to offer patients access to national protocols supported by the institute.

Unlike cervical or endometrial cancers, which develop from cells of the uterus, trophoblastic neoplasia starts in the cells that would normally develop into the placenta during pregnancy. These tumors include hydatidiform moles, caused by over-production of the tissue that typically develops into the placenta, and choriocarcinoma, a quick-growing form of cancer in a woman's uterus.

There has been no consensus on which drug and regimen best treats GTN, and researchers found that such choices were highly institution-specific.

In this trial, researchers compared regimens of both cancer drugs in a sample of 216 women enrolled over an eight-year period. Adverse effects
'/>"/>

Contact: Robin Russell
robin.russell@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Most women facing gynecologic surgery dont worry about its effects on sex
2. Targeted agent selumetinib shows promise in biliary cancer
3. Public session of the Cancer Drug Development Roundtable at Ohio State
4. New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds
5. Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer
6. Acupuncture May Help Ease Hot Flashes Tied to Prostate Cancer Treatment
7. Smoking Could Raise Odds for Advanced Kidney Cancer
8. ACE Inhibitors Seem to Raise Risk of Breast Cancer Recurrence
9. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
10. Acupuncture relieves hot flashes from prostate cancer treatment
11. Worm studies shed light on human cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... prom shopping reaching its final days, VogueQueen.com, a renowned ... its new and trendy apparels. Recently, the company has ... online shop. Additionally, it is now providing huge discounts ... to the company’s sales manager, the promotion will come ... He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Doylestown ... covering a variety of men’s health questions. Paddock ... specific to men, why women live longer than men, ... Men's Health Made Simple featured on Doylestown ... get a hernia at any age. If you notice ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... July 12, 2014 Floor-grade ... of 4.1 out of 5. This above-average score ... been underpinning buyer negotiation power over the three ... Anna Son, “during the period, surging demand for ... associated with new product development, have placed upward ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... sexual intercourse for couples lasts from 3 to 13 ... hours of sexual activity, according to a survey of ... Eric Corty and Jenay Guardiani conducted a survey of ... and Research, which include psychologists, physicians, social workers, marriage/family ...
... Will Arnett, Matthew Broderick, Steve Carell, Stephen, Colbert, ... James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, Sarah ... Insult Comic Dog And Many More To Be Announced, ... today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band Maroon ...
... Work in primates points to possible weapon against human ... News) -- Researchers have successfully tested several Ebola vaccines ... first human vaccine for one of the world,s deadliest ... cannot be overlooked. We are seeing more and more ...
... French . , Montreal, March 31, 2008 ... novel gene responsible for a significant fraction of ALS (sporadic ... Lou Gehrigs disease, an incurable neuromuscular disorder that affects motor ... five years. , Published in the current online edition of ...
... March 31 The Epilepsy,Foundation,s quick reaction to a ... raises awareness of the need for Web security for ... and those who,use its online forums for help, support, ... posted rapidly flashing images to cause,serious injury and harm. ...
... --- University of Florida chemists are the first to use ... diseases -- without any previous knowledge of what these microscopic ... in the online edition of the Journal of Proteome Research, ... improved treatment of some types of cancer as well as ...
Cached Medicine News:Health News:Good sexual intercourse lasts minutes, not hours, therapists say 2Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Researchers identify a gene responsible for cases of Lou Gehrig's disease 2Health News:Epilepsy Foundation Takes Action Against Hackers 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 3
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Clinical Program Leverages Quark,s RNAi Technology, FREMONT, ... pharmaceutical company discovering and developing novel,RNA interference (RNAi)-based ... patient dosing in a Phase II trial,evaluating, ... (DME)., PF-4523655 is a novel siRNA drug ...
... Does Not Mean the End of Anti-Amyloid,Therapies -, ... studies,of potential new treatments for Alzheimer,s - even ... field,s knowledge and point scientists,toward advances in therapies ... the 2008 Alzheimer,s Association International Conference,on Alzheimer,s Disease ...
Cached Medicine Technology:Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 3Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 2Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 3Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 5Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 6Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 7Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 8Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 9Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 10Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 11